These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 38953405)

  • 21. Childhood bullous pemphigoid: a clinicopathologic study and review of the literature.
    Fisler RE; Saeb M; Liang MG; Howard RM; McKee PH
    Am J Dermatopathol; 2003 Jun; 25(3):183-9. PubMed ID: 12775979
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bullous pemphigoid: Three main clusters defining 3 outcome profiles.
    Guerrois F; Hassan E; Bettuzzi T; Seta V; Goulvestre C; Jelti L; Belmondo T; Wolkenstein P; Aractingi S; Ingen-Housz-Oro S; Dupin N
    J Am Acad Dermatol; 2022 Aug; 87(2):359-365. PubMed ID: 35483492
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-BP180 and anti-BP230 enzyme-linked immunosorbent assays for diagnosis and disease activity tracking of bullous pemphigoid: A prospective cohort study.
    Chanprapaph K; Ounsakul V; Pruettivorawongse D; Thadanipon K
    Asian Pac J Allergy Immunol; 2021 Dec; 39(4):272-278. PubMed ID: 31175713
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Circulating bullous pemphigoid autoantibodies in the setting of negative direct immunofluorescence findings for bullous pemphigoid: A single-center retrospective review.
    Wang M; Lehman JS; Camilleri MJ; Drage LA; Wieland CN
    J Am Acad Dermatol; 2019 Aug; 81(2):472-479. PubMed ID: 30928465
    [TBL] [Abstract][Full Text] [Related]  

  • 25. More Severe Erosive Phenotype Despite Lower Circulating Autoantibody Levels in Dipeptidyl Peptidase-4 Inhibitor (DPP4i)-Associated Bullous Pemphigoid: A Retrospective Cohort Study.
    Ständer S; Schmidt E; Zillikens D; Ludwig RJ; Kridin K
    Am J Clin Dermatol; 2021 Jan; 22(1):117-127. PubMed ID: 33026629
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and Immunological Profiles of 14 Patients With Bullous Pemphigoid Without IgG Autoantibodies to the BP180 NC16A Domain.
    Nakama K; Koga H; Ishii N; Ohata C; Hashimoto T; Nakama T
    JAMA Dermatol; 2018 Mar; 154(3):347-350. PubMed ID: 29299596
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bullous Pemphigoid-Associated Mortality Rate in a Canadian Tertiary Referral Centre.
    Cyr P; Lim D; Caruana M; Pennou C; Lemieux A; Fortin B; Bolduc C
    J Cutan Med Surg; 2022; 26(4):386-392. PubMed ID: 35379013
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hospitalization, inpatient burden and comorbidities associated with bullous pemphigoid in the U.S.A.
    Ren Z; Hsu DY; Brieva J; Silverberg NB; Langan SM; Silverberg JI
    Br J Dermatol; 2017 Jan; 176(1):87-99. PubMed ID: 27343837
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of glucocorticosteroids, and old age.
    Rzany B; Partscht K; Jung M; Kippes W; Mecking D; Baima B; Prudlo C; Pawelczyk B; Messmer EM; Schuhmann M; Sinkgraven R; Büchner L; Büdinger L; Pfeiffer C; Sticherling M; Hertl M; Kaiser HW; Meurer M; Zillikens D; Messer G
    Arch Dermatol; 2002 Jul; 138(7):903-8. PubMed ID: 12071817
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Involvement of palms and soles in patients with autoimmune bullous diseases: a comparative analysis of a diagnostically relevant localization.
    Jałowska M; Spałek M; Bowszyc-Dmochowska M; Gornowicz-Porowska J; Dmochowski M
    Front Immunol; 2023; 14():1227855. PubMed ID: 37885886
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mucosal Involvement in Bullous Pemphigoid Is Mostly Associated with Disease Severity and to Absence of Anti-BP230 Autoantibody.
    Clapé A; Muller C; Gatouillat G; Le Jan S; Barbe C; Pham BN; Antonicelli F; Bernard P
    Front Immunol; 2018; 9():479. PubMed ID: 29662486
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and immunological profile of patients with dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid.
    Bellinato F; Maurelli M; Schena D; Gisondi P; Girolomoni G
    Ital J Dermatol Venerol; 2021 Aug; 156(4):455-459. PubMed ID: 32545941
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical characterization, treatment, and outcome of nivolumab-induced bullous pemphigoid.
    Liu M; Yuan M; Sun W; Li Z; Zhou X; Wang C
    Invest New Drugs; 2023 Dec; 41(6):802-807. PubMed ID: 37773473
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-BP180 autoantibody levels at diagnosis correlate with 1-year mortality rates in patients with bullous pemphigoid.
    Monshi B; Gulz L; Piringer B; Wiala A; Kivaranovic D; Schmidt M; Sesti A; Heil T; Vujic I; Posch C; Rappersberger K
    J Eur Acad Dermatol Venereol; 2020 Jul; 34(7):1583-1589. PubMed ID: 32170780
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Autoreactive Peripheral Blood T Helper Cell Responses in Bullous Pemphigoid and Elderly Patients With Pruritic Disorders.
    Didona D; Scarsella L; Fehresti M; Solimani F; Juratli HA; Göbel M; Mühlenbein S; Holiangu L; Pieper J; Korff V; Schmidt T; Sitaru C; Eming R; Hertl M; Pollmann R
    Front Immunol; 2021; 12():569287. PubMed ID: 33841390
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bullous pemphigoid in infants: characteristics, diagnosis and treatment.
    Schwieger-Briel A; Moellmann C; Mattulat B; Schauer F; Kiritsi D; Schmidt E; Sitaru C; Ott H; Kern JS
    Orphanet J Rare Dis; 2014 Dec; 9():185. PubMed ID: 25491396
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dyshidrosiform Bullous Pemphigoid: Case Reports and Review.
    Cohen PR
    Cureus; 2020 Jan; 12(1):e6630. PubMed ID: 32064205
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study.
    Marazza G; Pham HC; Schärer L; Pedrazzetti PP; Hunziker T; Trüeb RM; Hohl D; Itin P; Lautenschlager S; Naldi L; Borradori L;
    Br J Dermatol; 2009 Oct; 161(4):861-8. PubMed ID: 19566661
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum autoantibody reactivity in bullous pemphigoid is associated with neuropsychiatric disorders and the use of antidiabetics and antipsychotics: a large, prospective cohort study.
    Dikmen HO; Yilmaz K; Benoit S; Bernard P; Drenovska K; Gerdes S; Gläser R; Günther C; Homey B; Horváth ON; Huilaja L; Joly P; Kiritsi D; Meller S; Patsatsi A; Sárdy M; Schauer F; Shahid M; Sticherling M; Tasanen K; Vassileva S; Worm M; Zillikens D; Sadik CD; van Beek N; König IR; Schmidt E
    J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):2181-2189. PubMed ID: 35796163
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and immunologic factors associated with bullous pemphigoid relapse during the first year of treatment: a multicenter, prospective study.
    Fichel F; Barbe C; Joly P; Bedane C; Vabres P; Truchetet F; Aubin F; Michel C; Jegou J; Grange F; Antonicelli F; Bernard P
    JAMA Dermatol; 2014 Jan; 150(1):25-33. PubMed ID: 24226428
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.